Novel Therapeutics in Glaucoma Management

Author(s): Claudio Bucolo*, Chiara Bianca Maria Platania, Filippo Drago, Vincenza Bonfiglio, Michele Reibaldi, Teresio Avitabile, Maurizio Uva

Journal Name: Current Neuropharmacology

Volume 16 , Issue 7 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell death and alterations of visual field. Elevated intraocular pressure (IOP) is considered the main risk factor of glaucoma, even though other factors cannot be ruled out, such as epigenetic mechanisms.

Objective: An overview of the ultimate promising experimental drugs to manage glaucoma has been provided.

Results: In particular, we have focused on purinergic ligands, KATP channel activators, gases (nitric oxide, carbon monoxide and hydrogen sulfide), non-glucocorticoid steroidal compounds, neurotrophic factors, PI3K/Akt activators, citicoline, histone deacetylase inhibitors, cannabinoids, dopamine and serotonin receptors ligands, small interference RNA, and Rho kinase inhibitors.

Conclusions: The review has been also endowed of a brief chapter on last reports about potential neuroprotective benefits of anti-glaucoma drugs already present in the market.

Keywords: Glaucoma, anti-glaucoma drugs, intraocular pressure, retinal ganglion cells, purinergic ligands, Rho kinase inhibitors, dopamine ligands, nitric oxide, histone deacetylase inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 12 July, 2018
Page: [978 - 992]
Pages: 15
DOI: 10.2174/1570159X15666170915142727
Price: $65

Article Metrics

PDF: 39